Alphamab Oncology has announced research updates for their drug JSKN003, which were presented at the 2025 ASCO Annual Meeting held from May 30 to June 3. The updates are based on findings from two clinical studies, JSKN003-101 and JSKN003-102. JSKN003-101 is a first-in-human, open-label, multi-center phase I clinical study conducted in Australia, focusing on patients with advanced or metastatic solid tumors. Meanwhile, JSKN003-102 is a phase I/II clinical study carried out in China, targeting patients with advanced solid tumors. These studies evaluate the efficacy and safety of JSKN003 for various indications. Alphamab Oncology emphasizes its proprietary protein engineering platforms and aims to develop multifunctional biological drug candidates to benefit patients globally. However, the company advises cautious handling of its shares, as successful development and marketing of JSKN003 are not guaranteed.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。